THTX News and Press, Theratechnologies Inc. From 01/31/24

2024-01-31 10:00:03 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-24 10:01:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-24 07:25:27 ET More on Theratechnologies Theratechnologies stock slides as Egrifta review runs beyond FDA target date Upcoming FDA Decision: How likely is approval for EGRIFTA MDV? Seeking Alpha’s Quant Rating on Theratechnologies Historical ea...

FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity CRL does not impact commercial availability of EGRIFTA SV ® , the F4 formulation of tesamorelin, the only medication approved in the U.S. ...

2024-01-23 08:25:53 ET More on Pre-market losers & stocks. Mesoblast Has Major Hurdles Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast rises after cell therapy gets FDA rare pediatric disease designation MSP Recovery stock tu...

2024-01-23 08:17:43 ET Shares of Canadian biopharma firm Theratechnologies ( NASDAQ: THTX ) plunged 30% premarket on Tuesday after the U.S. health regulator said it will continue reviewing the supplemental license application for the company's F8 formulation of tesamorelin beyon...

FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company ...

2024-01-19 11:01:06 ET Company: Theratechnologies Inc. (THTX) Seeking Alpha Quant rating for THTX: Hold Wall Street Analysts’ Rating: Buy Seeking FDA Approval for  EGRIFTA MDV, which is the F8 formulation of tesamorelin. Type of Application: Supplemental ...

2024-01-02 10:47:47 ET This %Pharmaceutical company is addressing the medical needs of patients with HIV and may be starting the new year off right. %Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovat...

Trogarzo ® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission comes on the heels of the recent FDA approval of the Trogarzo ® IV push loading dose MONTREAL...